BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.
Company profile
Ticker
BLGO
Exchange
Website
CEO
Dennis P. Calvert
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Huntsman • Chemours • FMC • Ecovyst • Olin • Perimeter Solutions • GCP Applied • Innospec • Ingevity • Livent ...
Former names
NUWAY MEDICAL INC, NUWAY ENERGY INC, LATIN AMERICAN CASINOS INC
SEC CIK
Corporate docs
Subsidiaries
BioLargo Life Technologies, Inc. • ONM Environmental, Inc. • BioLargo Energy Technologies, Inc. • BioLargo Equipment Solutions & Technologies, Inc. • BioLargo Canada, Inc. • BioLargo Development Corp. • BioLargo Engineering, Science & Technologies, LLC • Clyra Medical Technologies, Inc. ...
IRS number
650159115
BLGO stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
24 Apr 24
EFFECT
Notice of effectiveness
24 Apr 24
EFFECT
Notice of effectiveness
24 Apr 24
POS EX
Additional exhibits for listing
15 Apr 24
POS EX
Additional exhibits for listing
15 Apr 24
S-1
IPO registration
12 Apr 24
POS AM
Prospectus update (post-effective amendment)
12 Apr 24
POS AM
Prospectus update (post-effective amendment)
12 Apr 24
RW
Registration withdrawal request
5 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
Transcripts
BLGO
Earnings call transcript
2023 Q4
2 Apr 24
BLGO
Earnings call transcript
2023 Q3
20 Nov 23
BLGO
Earnings call transcript
2023 Q2
16 Aug 23
BLGO
Earnings call transcript
2023 Q1
18 May 23
BLGO
Earnings call transcript
2022 Q4
3 Apr 23
BLGO
Earnings call transcript
2022 Q3
16 Nov 22
BLGO
Earnings call transcript
2021 Q4
5 Apr 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.04 mm | 3.04 mm | 3.04 mm | 3.04 mm | 3.04 mm | 3.04 mm |
Cash burn (monthly) | 177.67 k | (no burn) | 512.33 k | 415.83 k | 278.67 k | 193.50 k |
Cash used (since last report) | 1.21 mm | n/a | 3.50 mm | 2.84 mm | 1.90 mm | 1.32 mm |
Cash remaining | 1.83 mm | n/a | -455.36 k | 203.38 k | 1.14 mm | 1.72 mm |
Runway (months of cash) | 10.3 | n/a | -0.9 | 0.5 | 4.1 | 8.9 |
Institutional ownership, Q4 2022
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 23.00 k |
Total shares | 117.84 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
First American Trust, FSB | 117.84 k | $23.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 24 | Christina Elaine Bray | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.35 | 53,571 | 18.75 k | 639,282 |
31 Mar 24 | Linda Park | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.35 | 53,571 | 18.75 k | 639,282 |
31 Mar 24 | Strommen Jack B. | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.35 | 42,857 | 15.00 k | 1,858,327 |
31 Mar 24 | Marshall Dennis E | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.35 | 53,571 | 18.75 k | 4,217,256 |
28 Mar 24 | Marshall Dennis E | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.35 | 64,176 | 22.46 k | 4,163,685 |
31 Dec 23 | Christina Elaine Bray | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.168 | 111,607 | 18.75 k | 585,711 |
Press releases
BioLargo PFAS Removal Technology Meets New US Drinking Water Standards
15 Apr 24
BioLargo Achieved 108% Year-Over-Year Revenue Growth in 2023
2 Apr 24
BioLargo Year-End 2023 Earnings Results Webcast and Conference Call on Tuesday, April 2, 2024 – 5:00 PM Eastern Time
1 Apr 24
Gabelli Funds to Host 10th Annual Waste & Environmental Services Symposium Thursday, April 4, 2024
1 Apr 24
New Regulations May Be Coming To Combat Dangerous "Forever Chemicals" – This Cleantech Innovator Is Ready
22 Feb 24